Immunity from Suit Sample Clauses

Immunity from Suit. In the event that the exercise by Novartis and/or its Affiliates or sublicensees of the licenses and rights granted pursuant to this License Agreement would infringe during the term of this License Agreement a claim of an issued Patent Controlled by Infinity, and which Patent is not covered by the grant in Section 2.1, Infinity hereby grants to Novartis and its Affiliates or sublicensees a worldwide, non-exclusive, sublicensable, royalty-free license and immunity from suit by Infinity and its Affiliates under such issued Patent for Novartis, its Affiliates and or sublicensees to discover, research, develop, make, use, import, export, distribute, market, promote, offer for sale, and sell the Optioned Lead Program Compounds and the Licensed Drug Products in the Field.

Immunity from Suit. 13.1.29.1 In any proceedings taken against it in South Africa in relation to the Finance Documents to which it is a party, it will not be entitled to claim for itself or any of its assets immunity from suit, execution, attachment or other legal process. 13.1.29.2 The execution of the Finance Documents to which it is a party constitutes, and its exercise of its rights and performance of its obligations thereunder will constitute, private and commercial acts done and performed for private and commercial purposes.

Immunity from Suit. (a) As of the Closing Date, Seller hereby grants Buyer a worldwide, present, perpetual and fully prepaid immunity from suit for infringement of Seller's Intellectual Property provided such claim of infringement relates to Buyer's exercise of its rights and interests as herein described.

Immunity from Suit. Sanofi hereby grants to Ascendis a free right (the “Immunity”) to practise any patent that may be applied for, filed by or delivered to Sanofi Covering an Improvement relating to Manufacturing (a “Manufacturing Patent”) and/or an Improvement relating to any medical device that is not a Sanofi Medical Device (“Medical Device Improvement Patent”) outside Diabetes. The term of the Immunity shall be for the duration of such Manufacturing Patent or Medical Device Improvement Patent, as applicable. The Immunity shall be transferable and/or extendable by Ascendis only to its licensees and/or Sub-Licensees for activities and products outside Diabetes, without any right for such licensees or Sub-Licensees to themselves transfer or extend the Immunity to another party, including by way of business purchase, merger or otherwise. Ascendis shall promptly inform Sanofi in writing after completion of any such transaction with such licensees and/or Sub-Licensees involving a transfer or extension by Ascendis of the Immunity hereby granted, and such notice shall include the identity of such licensees and/or Sub-Licensees and a description of the therapeutic field (but not the financial terms) of the licences granted. For clarity, the Immunity hereby granted to Ascendis does not create any obligation on Sanofi to disclose to Ascendis any Technical Information relating to a Manufacturing Improvement or to a Sanofi Medical Device.

Immunity from Suit. In any proceedings taken in England in relation to any of the Note Documents, none of the Obligors shall be entitled to claim for itself or any of its assets immunity from suit, execution, attachment or other legal process.

Immunity from Suit. To the extent that the Tenant, the Developer, the Tenant's Surety or ITOCHU is entitled to any right of immunity from any judicial proceedings, from the granting of any form of relief in any proceedings, from attachment of its property or assets, or from execution of judgment, on the ground of sovereignty diplomatic immunity or otherwise in respect of any matter arising out of or relating to its obligations under this Agreement, the Tenant, the Developer, the Tenant's Surety and ITOCHU each hereby and will irrevocably waive such right for the benefit of the other relevant parties and agree not to invoke such right and consent to the giving of any such relief or the issue of any such proceeding or process of attachment or execution by the other relevant party.

Immunity from Suit. (a) The Members of the Tribunal shall not be required by either Party to be a party or witness in any judicial or other proceedings arising out of this arbitration. (b) The Members of the Tribunal shall not be liable to either Party in respect of any act or omission in connection with any matter related to this arbitration, save where the Arbitrator is shown to have been guilty of conscious and deliberate wrongdoing, or gross negligence. (c) Save for conscious and deliberate wrongdoing or gross negligence: (i) the Parties undertake not to initiate legal proceedings against, or in any other manner impair the independence and/or immunity of, the Members of the Tribunal in respect of any act or omission in connection with this arbitration; (ii) the Members of the Tribunal shall not be liable to either Party in respect of any act or omission in connection with any matter related to this arbitration; and (iii) the Parties agree jointly and severally to indemnify the Members of the Tribunal in respect of any liability, cost or claim in relation to this arbitration.

Immunity from Suit. No Obligor and no Target (if not yet an Obligor) nor any of its respective assets is entitled to immunity from suit, execution, attachment or other legal process in any jurisdiction. The entry by each Obligor into this Agreement and the other Loan Documents to which it is party constitutes, and the exercise of its respective rights and performance of and compliance with its respective obligations under this Agreement and the other Loan Documents will constitute, private and commercial acts done and performed for private and commercial purposes.

Immunity from Suit. Synbiotics hereby grants an immunity from suit for infringement under the ‘631 Patent to Agen’s customers and its distributors’, resellers’, and OEMs’ customers with respect to such customers’ use of: (a) CHW Kits that contain CHW Antibody, and (b) CHW Kits that contain CHW Antibody Derivatives, provided, in each case, that such CHW Kits are made by or for Agen and meet the conditions set forth in clauses (ii) and (iii) of Section 3.2. For the avoidance of doubt, for purposes of this Agreement the term “CHW Antibody” includes the antibody identified in Section 8.1 as “55-2500 Anti-CHW MAb, clone key DI16872.5-USDA code E118.00”.